Although a larger dataset of molecular and pathological data is necessary for a conclusive determination, these observations strongly imply that SMARCA4 deficiency might act as a significant oncogenic driver, potentially leading to a highly aggressive cancer phenotype, regardless of its anatomical origin. Here, SMARCA4 is linked to cancer.